skip to Main Content

Choosing the right patient for 3C Patch®

The 3C Patch® has been extensively studied providing both in vitro and clinical data. The initial primary emphasis has been on developing an evidence base for hard-to-heal diabetic foot ulcers.

The recently published RCT1 for 3C Patch® represents a long-awaited addition to the body of evidence for regenerative medicine.

3C Patch® is cleared by the FDA for the management of exuding wounds, such as leg ulcers, pres­sure ulcers, and diabetic ulcers and mechanically or surgically debrided wounds.

The product is CE marked in Europe. The intended use of the product is to produce an autologous platelet-rich fibrin for wound management of recalcitrant wounds. 3C Patch® will be the new name for Leucopatch® during 2019.

3C Patch® System

Clinical Pratice

DFU Challenge

Biological Science

FAQ

Back To Top